spacer
home > ict > summer 2018 > perfecting practices
PUBLICATIONS
International Clinical Trials

Perfecting Practices

Over the past decade, the focus on technology as a driver of performance improvement in clinical trials has been intense (1- 2). This is particularly true for study start-up, a widely recognised bottleneck encompassing the activities associated with site identification, feasibility assessment, selection, and activation required before the first patient can be enrolled in a study.

Practices intended to streamline study start-up timelines include the use of technology investments to expedite the collection of clinical data and to help sponsors/CROs better monitor clinical trial performance, but, despite many attempts at improvement within organisations, gains in end-to-end cycle time have not been made (3).

A comprehensive survey conducted by the Tufts Center for the Study of Drug Development determined that a mere 8% of sponsors and 14% of CROs are extremely satisfied with their study start-up processes (4). By comparison, approximately 40% are either somewhat or completely unsatisfied with those methods. Respondents reporting that they are extremely satisfied have cycle times 57.5% shorter than those claiming to be completely unsatisfied.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Craig Morgan is a technology and life sciences management professional with more than 15 years of experience in the application of informatics and bioinformatics to drug discovery. He currently heads up the marketing and brand development functions at goBalto, working with sponsors, CROs, and sites to reduce cycle times and improve collaboration and oversight in clinical trials.
spacer
Craig Morgan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemeras preservative-free multidose eye dropper Novelia® approved for Santens Cosopt® for Glaucoma treatments in 29 European countries

Nemera is pleased to announce that its multidose eye dropper Novelia® has been approved for the preservative-free formulation Cosopt iMulti® (20mg/ml dorzolamide + 5mg/ml timolol eye drops, solution).
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement